Novel targets for the treatment of obesity: a review of progress

The escalating problem of obesity has initiated an unprecedented search for novel anti-obesity drugs. This article reviews the wealth of central and peripheral targets that have been discovered recently. Some of the newer agents appear to have improved efficacy over current drugs, whereas others also have potential to treat the co-morbid risk factors associated with obesity. Future strategies are likely to combine drugs with complementary central and peripheral mechanisms of action to enhance therapeutic benefit.

[1]  H. Kotani,et al.  Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype. , 2002, The Journal of clinical investigation.

[2]  K. Gadde,et al.  Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. , 2002, Obesity research.

[3]  B. Kennedy,et al.  Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. , 1999, Science.

[4]  C. Laudeman,et al.  CCK1R agonists: a promising target for the pharmacological treatment of obesity. , 2003, Current topics in medicinal chemistry.

[5]  C. Dourish,et al.  Serotonin receptor ligands and the treatment of obesity. , 2004, Current opinion in investigational drugs.

[6]  M. Véniant,et al.  Leptin: from animals to humans. , 2003, Current pharmaceutical design.

[7]  C. Collins,et al.  Prospects for obesity treatment: MCH receptor antagonists. , 2003, Current opinion in investigational drugs.

[8]  N. Levens,et al.  Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs. , 2003, Current opinion in investigational drugs.

[9]  G. Ronnett,et al.  Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass. , 2004, American journal of physiology. Endocrinology and metabolism.

[10]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[11]  S. O’Rahilly,et al.  Melanocortin receptors weigh in , 2004, Nature Medicine.

[12]  P. Puigserver,et al.  Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. , 2003, Endocrine reviews.

[13]  Beth Borowsky,et al.  Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist , 2002, Nature Medicine.

[14]  M. Bednarek,et al.  Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. , 2003, European journal of pharmacology.

[15]  T. Horvath,et al.  Ghrelin as a potential anti-obesity target. , 2003, Current pharmaceutical design.

[16]  A. Hancock.  H3 receptor antagonists/inverse agonists as anti-obesity agents. , 2003, Current opinion in investigational drugs.

[17]  J. Flier,et al.  A Transgenic Model of Visceral Obesity and the Metabolic Syndrome , 2001, Science.

[18]  R. Cone,et al.  The central melanocortin system can directly regulate serum insulin levels. , 2000, Endocrinology.

[19]  A. Sleight,et al.  A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze , 2001, Neuropharmacology.

[20]  M. Bickerdike.  5-HT2C receptor agonists as potential drugs for the treatment of obesity. , 2003, Current topics in medicinal chemistry.

[21]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Batterham,et al.  The Gut Hormone Peptide YY Regulates Appetite , 2003, Annals of the New York Academy of Sciences.

[23]  Robert V Farese,et al.  Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat , 2000, Nature Genetics.

[24]  G. W. Price,et al.  Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. , 2003, Molecular pharmacology.

[25]  B. Conway-Campbell,et al.  Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment , 2001, International Journal of Obesity.

[26]  R. Gianello,et al.  Metabolic Studies of a Synthetic Lipolytic Domain (AOD9604) of Human Growth Hormone , 2001, Hormone Research in Paediatrics.

[27]  Johan Malm,et al.  Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Wakil,et al.  Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  John Saunders,et al.  The melanocortin system and its role in obesity and cachexia. , 2003, Current topics in medicinal chemistry.